EP1226150A4 - Tadg-15: une serine protease extracellulaire surexprimee dans des carcinomes - Google Patents

Tadg-15: une serine protease extracellulaire surexprimee dans des carcinomes

Info

Publication number
EP1226150A4
EP1226150A4 EP00973739A EP00973739A EP1226150A4 EP 1226150 A4 EP1226150 A4 EP 1226150A4 EP 00973739 A EP00973739 A EP 00973739A EP 00973739 A EP00973739 A EP 00973739A EP 1226150 A4 EP1226150 A4 EP 1226150A4
Authority
EP
European Patent Office
Prior art keywords
tadg
carcinomas
serine protease
extracellular serine
protease overexpressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00973739A
Other languages
German (de)
English (en)
Other versions
EP1226150A1 (fr
Inventor
Timothy J O'brien
Hirotoshi Tanimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arkansas
Original Assignee
University of Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/421,213 external-priority patent/US7022821B1/en
Application filed by University of Arkansas filed Critical University of Arkansas
Priority to EP07118615A priority Critical patent/EP1887082A3/fr
Publication of EP1226150A1 publication Critical patent/EP1226150A1/fr
Publication of EP1226150A4 publication Critical patent/EP1226150A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP00973739A 1999-10-20 2000-10-20 Tadg-15: une serine protease extracellulaire surexprimee dans des carcinomes Withdrawn EP1226150A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07118615A EP1887082A3 (fr) 1999-10-20 2000-10-20 TADG-15: Une serine protease extracellulaire superexprimée dans des carcinomes

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US421213 1989-10-13
US09/421,213 US7022821B1 (en) 1998-02-20 1999-10-20 Antibody kit for the detection of TADG-15 protein
PCT/US2000/029095 WO2001029056A1 (fr) 1999-10-20 2000-10-20 Tadg-15: une serine protease extracellulaire surexprimee dans des carcinomes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07118615A Division EP1887082A3 (fr) 1999-10-20 2000-10-20 TADG-15: Une serine protease extracellulaire superexprimée dans des carcinomes

Publications (2)

Publication Number Publication Date
EP1226150A1 EP1226150A1 (fr) 2002-07-31
EP1226150A4 true EP1226150A4 (fr) 2005-05-25

Family

ID=23669632

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07118615A Withdrawn EP1887082A3 (fr) 1999-10-20 2000-10-20 TADG-15: Une serine protease extracellulaire superexprimée dans des carcinomes
EP00973739A Withdrawn EP1226150A4 (fr) 1999-10-20 2000-10-20 Tadg-15: une serine protease extracellulaire surexprimee dans des carcinomes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP07118615A Withdrawn EP1887082A3 (fr) 1999-10-20 2000-10-20 TADG-15: Une serine protease extracellulaire superexprimée dans des carcinomes

Country Status (6)

Country Link
EP (2) EP1887082A3 (fr)
JP (1) JP2003512036A (fr)
AU (1) AU774106B2 (fr)
CA (1) CA2388450C (fr)
MX (1) MXPA02004046A (fr)
WO (1) WO2001029056A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022100B1 (en) 1999-09-03 2006-04-04 A-Med Systems, Inc. Guidable intravascular blood pump and related methods
US7795211B2 (en) * 2000-02-22 2010-09-14 Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
US7157596B2 (en) 2000-09-08 2007-01-02 Dendreon Corporation Inhibitors of serine protease activity of matriptase or MTSP1
US7019019B2 (en) 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
WO2006068975A2 (fr) 2004-12-20 2006-06-29 Abgenix, Inc. Proteines de liaison specifiques de la matriptase humaine
GB0611116D0 (en) * 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
WO2009020645A2 (fr) * 2007-08-07 2009-02-12 Oxford Genome Sciences (Uk) Ltd. Protéine de matriptase et utilisations de celle-ci
CA2761310C (fr) 2009-05-07 2017-02-28 Charles S. Craik Anticorps et procedes d'utilisation de ceux-ci
US8455200B2 (en) 2009-10-15 2013-06-04 Traxxsson, Llc Measurement of PKA for cancer detection
CA2811000A1 (fr) 2010-09-09 2012-03-15 Traxxsson, Llc Procedes combines de diagnostic d'un cancer chez un patient
US9255155B2 (en) 2013-01-31 2016-02-09 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer
JP2016538852A (ja) 2013-11-25 2016-12-15 オックスフォード バイオセラピューティックス リミテッドＯｘｆｏｒｄ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ がん治療のための抗体抗マトリプターゼ
US9272027B1 (en) 2014-09-08 2016-03-01 The United States Of America As Represented By The Secretary Of The Air Force Francisella tularensis live vaccine strains and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041656A1 (fr) * 1997-03-19 1998-09-24 The Board Of Trustees Of The University Of Arkansas Compositions et methodes pour le diagnostic precose du cancer ovarien
WO1999036550A2 (fr) * 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Molecules de proteases humaines
WO1999042120A1 (fr) * 1998-02-20 1999-08-26 The Board Of Trustees Of The University Of Arkansas Serine protease extracellulaire surexprimee dans les cancers du sein ou les cancers ovariens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09149790A (ja) * 1995-09-29 1997-06-10 Suntory Ltd 新規セリンプロテアーゼ
CA2360464A1 (fr) * 1999-01-11 2000-07-20 Incyte Pharmaceuticals, Inc. Peptidases humaines
CA2362670A1 (fr) * 1999-03-12 2000-09-14 Georgetown University Matriptase, protease de la serine, et son utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041656A1 (fr) * 1997-03-19 1998-09-24 The Board Of Trustees Of The University Of Arkansas Compositions et methodes pour le diagnostic precose du cancer ovarien
WO1999036550A2 (fr) * 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Molecules de proteases humaines
WO1999042120A1 (fr) * 1998-02-20 1999-08-26 The Board Of Trustees Of The University Of Arkansas Serine protease extracellulaire surexprimee dans les cancers du sein ou les cancers ovariens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0129056A1 *

Also Published As

Publication number Publication date
EP1887082A3 (fr) 2008-06-11
AU774106B2 (en) 2004-06-17
MXPA02004046A (es) 2002-10-11
EP1887082A2 (fr) 2008-02-13
EP1226150A1 (fr) 2002-07-31
CA2388450A1 (fr) 2001-04-26
WO2001029056A1 (fr) 2001-04-26
AU1221501A (en) 2001-04-30
JP2003512036A (ja) 2003-04-02
CA2388450C (fr) 2013-02-12

Similar Documents

Publication Publication Date Title
ZA992447B (en) Quinoxalinones as serine protease inhibitors.
EP1157035A4 (fr) Serine protease transmembranaire surexprimee dans le carcinome ovarien et ses applications
AU139162S (en) Footwear
ZA992448B (en) Quinoxalinones as serine protease inhibitors.
HK1054571A1 (zh) 新的蛋白酶
AU140155S (en) Footwear
AU2001269448A1 (en) Water supply
SG106633A1 (en) Polishing system
EP1226150A4 (fr) Tadg-15: une serine protease extracellulaire surexprimee dans des carcinomes
EP1179052A4 (fr) Serine proteases
GB9800817D0 (en) Serine protease inhibitors
EP1244780A4 (fr) Adn codant la serine protease t humaine
AU2002343025A8 (en) Improvements in footwear
AU5290499A (en) Human htra serine protease
SG96553A1 (en) Abrasive
AU1368002A (en) Sander
AU1624501A (en) Human serine protease
GB0107142D0 (en) Comminution machine
EP1132473A4 (fr) Nouvelle serine protease bssp6
EP1206233A4 (fr) Serine proteases
EP1214401A4 (fr) Adn codant la serine protease humaine c-e
EP1132477A4 (fr) Nouvelles serine proteases bssp4
AU2542100A (en) Protease
AU2001238721A1 (en) Human serine protease
GB2361621B (en) Footwear

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020419

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050406

17Q First examination report despatched

Effective date: 20050928

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071030